Clinical study of COAD-B regimen in treatment of patients with relapsed/refractory non-Hodgkin lymphoma / 中华血液学杂志
Chinese Journal of Hematology
; (12): 857-861, 2013.
Article
in Zh
| WPRIM
| ID: wpr-272100
Responsible library:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the efficacy, adverse events and long-term survival of cyclophosphamide, vindesine, cytarabine, dexamethasone and bleomycin (COAD-B) regimen for relapsed and refractory non-Hodgkin lymphoma (NHL).</p><p><b>METHODS</b>Eighty six patients diagnosed with relapsed or refractory NHL were included in our study from January 2007 to January 2013. The chemotherapy regimen was COAD-B, the therapeutic efficacy was evaluated every 2 courses. Once the stable disease (SD) or progress of the disease (PD) achieved, the patients would switch to other second-line regimens.</p><p><b>RESULTS</b>The overall response rate (ORR) was 67.4%, median remission duration was 13 months (3-51 months); 1-,2- and 4-year overall survival (OS) rates were 75.4%, 56.8% and 40.0%, respectively; 1-, 2- and 4-year progression-free survival (PFS) rates were 50.3%, 39.4% and 27.5%, respectively. The main adverse reaction of patients was myelosuppression. The response to chemotherapy and long- term survival of the relapsed patients were significantly better than that of the refractory ones, and the difference had statistical significance.</p><p><b>CONCLUSION</b>COAD-B could be the salvage regimen for relapsed and refractory NHL.</p>
Full text:
1
Index:
WPRIM
Main subject:
Bleomycin
/
Lymphoma, Non-Hodgkin
/
Remission Induction
/
Vindesine
/
Dexamethasone
/
Antineoplastic Combined Chemotherapy Protocols
/
Survival Rate
/
Treatment Outcome
/
Salvage Therapy
/
Disease-Free Survival
Limits:
Humans
Language:
Zh
Journal:
Chinese Journal of Hematology
Year:
2013
Type:
Article